FAKTOR OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 08:01:06 21/06/2024 BST | ||
| 0.707 EUR | +2.17% |
|
| Current month | +7.79% | ||
| 1 month | -17.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 0.707 | +2.17% |
| 20/06/24 | 0.692 | +4.69% |
| 19/06/24 | 0.661 | +1.69% |
| 18/06/24 | 0.65 | +6.56% |
| 17/06/24 | 0.61 | +12.96% |
Real-time BOERSE MUENCHEN
Last update June 21, 2024 at 08:01 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GK5U5A |
| ISIN | DE000GK5U5A0 |
| Date issued | 01/06/2022 |
| Strike | 262.3 $ |
| Maturity | Unlimited |
| Parity | 62.95 : 1 |
| Emission price | 3.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.66 € |
|---|---|
| Lowest since issue | 0.258 € |
| Spread | 0.01 € |
| Spread % | 1.39% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.9
USD
Average target price
316.4
USD
Spread / Average Target
+2.11%
- Stock Market
- Certificates
- Certificat
